Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Taysha Gene Therapies price target raised to $67.50 from $60 at Chardan » 12:16
04/12/21
04/12
12:16
04/12/21
12:16
TSHA

Taysha Gene Therapies

$24.94 /

+3.77 (+17.81%)

Chardan analyst Gbola…

Chardan analyst Gbola Amusa raised the firm's price target on Taysha Gene Therapies to $67.50 from $60 and keeps a Buy rating on the shares after the company announced the acquisition of exclusive worldwide rights to AAV9-based gene therapy TSHA-120 for giant axonal neuropathy. The deal potentially transforms Taysha into a pivotal-stage gene therapy company, Amusa tells investors in a research note. TSHA-120 has received FDA Pediatric Disease and Orphan Drug designations, and with an estimated 2,400 patients in the U.S. and Europe, the program could represent a near-term commercial opportunity of greater than $2B, says the analyst.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$24.94 /

+3.77 (+17.81%)

TSHA Taysha Gene Therapies
$24.94 /

+3.77 (+17.81%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
TSHA Taysha Gene Therapies
$24.94 /

+3.77 (+17.81%)

  • 24
    Sep
Conference/Events
Needham to hold a virtual conference » 09:12
04/12/21
04/12
09:12
04/12/21
09:12
GRCL

Gracell

$13.52 /

-0.82 (-5.72%)

, LMAT

LeMaitre

$51.38 /

+0.82 (+1.62%)

, IONS

Ionis Pharmaceuticals

$42.32 /

-0.32 (-0.75%)

, TSHA

Taysha Gene Therapies

$21.35 /

+1.49 (+7.50%)

, ZEAL

Zealand Pharma

$33.60 /

+1.27 (+3.93%)

, CLSD

Clearside Biomedical

$2.66 /

+0.12 (+4.72%)

, MEIP

MEI Pharma

$3.43 /

+0.12 (+3.63%)

, PCVX

Vaxcyte

$20.27 /

-0.49 (-2.36%)

, EVLO

Evelo Biosciences

$10.03 /

+0.005 (+0.05%)

, IVC

Invacare

$8.23 /

-0.08 (-0.96%)

, BSGM

BioSig Technologies

$4.59 /

+0.12 (+2.68%)

, CYTK

Cytokinetics

$24.17 /

+0.01 (+0.04%)

, SYBX

Synlogic

$3.34 /

-0.02 (-0.60%)

, RNA

Avidity Biosciences

$22.12 /

-1.8 (-7.53%)

, CSTL

Castle Biosciences

$69.44 /

-1.2 (-1.70%)

, AGI

Alamos Gold

$8.37 /

+0.08 (+0.97%)

, CARA

Cara Therapeutics

$29.09 /

+1.645 (+5.99%)

, FIX

Comfort Systems USA

$79.11 /

+1.925 (+2.49%)

, ITRM

Iterum Therapeutics

$1.30 /

-0.305 (-19.00%)

, LTRN

Lantern Pharma

$17.05 /

-0.13 (-0.76%)

, OCGN

Ocugen

$6.96 /

+0.045 (+0.65%)

, QURE

uniQure

$33.77 /

-1.75 (-4.93%)

, STTK

Shattuck Labs

$28.31 /

+1.365 (+5.07%)

, VKTX

Viking Therapeutics

$5.93 /

-0.23 (-3.73%)

20th Annual Virtual…

20th Annual Virtual Healthcare Virtual Conference will be held on April 12-15.

ShowHide Related Items >><<
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

IVC Invacare
$8.23 /

-0.08 (-0.96%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

02/03/21 Citi
Gracell initiated with a Buy at Citi
02/02/21 Jefferies
Gracell initiated with a Buy at Jefferies
02/02/21 Wells Fargo
Gracell initiated with an Overweight at Wells Fargo
02/02/21 Piper Sandler
Gracell initiated with an Overweight at Piper Sandler
LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

02/26/21 Barrington
LeMaitre price target raised to $49 from $47 at Barrington
02/12/21
Fly Intel: Top five analyst initiations
02/12/21 KeyBanc
LeMaitre initiated with a Sector Weight at KeyBanc
02/11/21 KeyBanc
LeMaitre initiated with a Sector Weight at KeyBanc
IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
05/29/20
Fly Intel: Top five analyst initiations
PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
07/07/20
Fly Intel: Top five analyst initiations
07/07/20 BofA
Vaxcyte initiated with a Buy at BofA
07/07/20 Jefferies
Vaxcyte initiated with a Buy at Jefferies
EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

04/12/21 Jefferies
Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum
04/12/21 Jefferies
Evelo Biosciences upgraded to Buy from Hold at Jefferies
03/12/21 Chardan
Evelo Biosciences price target raised to $15 from $10 at Chardan
01/25/21 JMP Securities
Evelo Biosciences price target raised to $36 from $27 at JMP Securities
IVC Invacare
$8.23 /

-0.08 (-0.96%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

03/09/21 Baird
Castle Biosciences price target lowered to $82 from $87 at Baird
02/03/21 KeyBanc
Castle Biosciences price target raised to $90 from $70 at KeyBanc
01/26/21 Canaccord
Castle Biosciences price target raised to $84 from $80 at Canaccord
01/15/21 SVB Leerink
Castle Biosciences price target raised to $80 from $70 at SVB Leerink
AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

02/10/21 JPMorgan
Alamos Gold initiated with a Neutral at JPMorgan
02/08/21 CIBC
Alamos Gold price target lowered to C$16 from C$19.25 at CIBC
02/02/21 National Bank
Alamos Gold price target lowered to C$14.50 from C$15.50 at National Bank
01/11/21 National Bank
Alamos Gold price target lowered to C$15.50 from C$16 at National Bank
CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

12/29/20 H.C. Wainwright
H.C. Wainwright reiterates $33 target on Cara after new drug filing
10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

07/29/20 DA Davidson
Comfort Systems USA price target raised to $45 from $32 at DA Davidson
04/29/20 DA Davidson
Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
04/29/20 DA Davidson
Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
04/20/20 Sidoti
Comfort Systems USA downgraded to Neutral from Buy at Sidoti
ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

03/31/21
Ocugen participates in a conference call with Cantor Fitzgerald
03/16/21 Roth Capital
Covaxin chances of U.S. approval now increased, says Roth Capital
03/04/21 Roth Capital
Ocugen price target raised to $10 from $9 at Roth Capital
03/04/21 Roth Capital
Roth boosts Ocugen target after partnered vaccine shows 'broad' efficacy
QURE uniQure
$33.77 /

-1.75 (-4.93%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

02/18/21 Chardan
Chardan trims Viking Therapeutics target to $19 as COVID pushes out Voyage data
09/11/20 B. Riley
Viking Therapeutics price target raised to $15 from $12 at B. Riley FBR
09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

IVC Invacare
$8.23 /

-0.08 (-0.96%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

  • 29
    Jan
  • 15
    Jan
  • 08
    Jan
  • 16
    Dec
  • 09
    Oct
  • 24
    Sep
  • 17
    Jul
  • 25
    Jun
  • 25
    Jun
  • 11
    Jun
  • 12
    Jun
  • 12
    Jun
OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

Hot Stocks
Taysha Gene Therapies acquires exclusive rights to AAV9 gene therapy program » 07:05
04/12/21
04/12
07:05
04/12/21
07:05
TSHA

Taysha Gene Therapies

$21.35 /

+1.49 (+7.50%)

Taysha Gene Therapies…

Taysha Gene Therapies announced the acquisition of exclusive worldwide rights to a clinical-stage AAV9 gene therapy program, now known as TSHA-120, for the treatment of giant axonal neuropathy, or GAN. TSHA-120 is an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health, or NIH, in close collaboration with a patient advocacy group focused on finding treatments and cures for GAN. TSHA-120 has received rare pediatric disease and orphan drug designations from the FDA for the treatment of GAN. The National Institute of Neurological Disorders and Stroke, or NINDS, division of the NIH is conducting the ongoing open-label, non-randomized, dose-escalation clinical trial of TSHA-120 for the treatment of GAN. The primary endpoint is safety, with secondary endpoints measuring efficacy using pathologic, physiologic, functional, and clinical markers. A primary measure of clinical efficacy is the Motor Function Measure 32 score, a quantitative scale designed to assess the severity and progression of motor function abilities. There is precedent for its use in multiple clinical studies for neuromuscular diseases, including spinal muscular atrophy amongst others. To date, 14 patients have been dosed with one of four dose levels of TSHA-120. TSHA-120 has demonstrated a dose-response relationship with arrest of disease progression at the second-highest dose level (1.8x1014 total vector genomes at one-year post-treatment, affecting a statistically significant eight-point improvement on the MFM32 score. A 4-point change on the MFM32 score is considered clinically meaningful. Six of these patients treated at therapeutic dose levels have shown sustained dose-dependent improvements in MFM32 scores for more than three years. Long-term results demonstrated that treatment with TSHA-120 at multiple dose levels was well-tolerated with no severe drug-related adverse events. Additional data are expected later this year, including results from the highest dose cohort. Before the end of the year, Taysha intends to request an End-of-Phase meeting with the FDA and engage with the European Medicines Agency, or EMA, and the Pharmaceuticals and Medical Devices Agency, or PMDA)in Japan to discuss the regulatory pathway for TSHA-120. Taysha expects to provide a regulatory and clinical update on TSHA-120, including data from the 3.5x1014 total vg cohort by year-end. Under the terms of the agreement, in exchange for granting Taysha the exclusive worldwide rights to TSHA-120, the GAN patient advocacy group will receive an upfront payment of $5.5M and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3M, as well as a low, single-digit royalty on net sales upon commercialization of the product.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

  • 24
    Sep
Conference/Events
Stifel to hold a virtual conference » 04:55
04/01/21
04/01
04:55
04/01/21
04:55
SAGE

Sage Therapeutics

$74.85 /

+1.82 (+2.49%)

, PRAX

Praxis Precision Medicines

$32.86 /

+3.25 (+10.98%)

, CERE

Cerevel Therapeutics

$13.73 /

+1.36 (+10.99%)

, KRTX

Karuna Therapeutics

$119.93 /

+2.66 (+2.27%)

, PASG

Passage Bio

$17.55 /

+0.8 (+4.78%)

, TSHA

Taysha Gene Therapies

$20.21 /

-0.33 (-1.61%)

, BIIB

Biogen

$280.05 /

+4.17 (+1.51%)

, XENE

Xenon Pharmaceuticals

$17.94 /

+0.59 (+3.40%)

, STOK

Stoke Therapeutics

$38.92 /

+1.89 (+5.10%)

, ZGNX

Zogenix

$19.52 /

+0.33 (+1.72%)

, AVDL

Avadel Pharmaceuticals

$9.11 /

+0.28 (+3.17%)

, QURE

uniQure

$33.75 /

+0.53 (+1.60%)

Stifel Virtual CNS Day…

Stifel Virtual CNS Day 2021 will be held on March 31-April 1.

ShowHide Related Items >><<
ZGNX Zogenix
$19.52 /

+0.33 (+1.72%)

XENE Xenon Pharmaceuticals
$17.94 /

+0.59 (+3.40%)

TSHA Taysha Gene Therapies
$20.21 /

-0.33 (-1.61%)

STOK Stoke Therapeutics
$38.92 /

+1.89 (+5.10%)

SAGE Sage Therapeutics
$74.85 /

+1.82 (+2.49%)

QURE uniQure
$33.75 /

+0.53 (+1.60%)

PRAX Praxis Precision Medicines
$32.86 /

+3.25 (+10.98%)

PASG Passage Bio
$17.55 /

+0.8 (+4.78%)

KRTX Karuna Therapeutics
$119.93 /

+2.66 (+2.27%)

CERE Cerevel Therapeutics
$13.73 /

+1.36 (+10.99%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

AVDL Avadel Pharmaceuticals
$9.11 /

+0.28 (+3.17%)

SAGE Sage Therapeutics
$74.85 /

+1.82 (+2.49%)

02/26/21 Mizuho
Sage Therapeutics downgraded to Neutral from Buy at Mizuho
02/25/21 Oppenheimer
Sage Therapeutics price target raised to $102 from $90 at Oppenheimer
02/25/21 H.C. Wainwright
Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright
02/24/21 Stifel
Stifel cuts Sage target to $121, reiterates Buy after quarterly results
PRAX Praxis Precision Medicines
$32.86 /

+3.25 (+10.98%)

03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
11/17/20 Piper Sandler
Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
11/11/20
Fly Intel: Top five analyst initiations
CERE Cerevel Therapeutics
$13.73 /

+1.36 (+10.99%)

12/10/20 Goldman Sachs
Cerevel Therapeutics initiated with a Buy at Goldman Sachs
11/23/20 Jefferies
Cerevel Therapeutics initiated with a Buy at Jefferies
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Stifel
Cerevel Therapeutics initiated with a Buy at Stifel
KRTX Karuna Therapeutics
$119.93 /

+2.66 (+2.27%)

03/22/21 BofA
Karuna Therapeutics initiated with a Buy at BofA
03/01/21 Oppenheimer
Karuna Therapeutics price target raised to $148 from $135 at Oppenheimer
02/26/21 Mizuho
Karuna Therapeutics price target raised to $150 from $116 at Mizuho
02/26/21 JMP Securities
Karuna Therapeutics price target raised to $167 from $122 at JMP Securities
PASG Passage Bio
$17.55 /

+0.8 (+4.78%)

03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
02/04/21
Fly Intel: Top five analyst initiations
TSHA Taysha Gene Therapies
$20.21 /

-0.33 (-1.61%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
BIIB Biogen
$280.05 /

+4.17 (+1.51%)

03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/25/21 Mizuho
Two 'low probability' Biogen events could drive upside, says Mizuho
03/23/21 Piper Sandler
Neurologist survey shows erosion for Biogen franchises, says Piper Sandler
02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
XENE Xenon Pharmaceuticals
$17.94 /

+0.59 (+3.40%)

10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
STOK Stoke Therapeutics
$38.92 /

+1.89 (+5.10%)

03/29/21 Canaccord
Stoke Therapeutics weakness a buying opportunity, says Canaccord
03/11/21 Canaccord
Stoke Therapeutics price target raised to $76 from $72 at Canaccord
03/10/21 Credit Suisse
Stoke Therapeutics price target raised to $58 from $49 at Credit Suisse
02/10/21 Wedbush
Stoke Therapeutics downgraded to Neutral at Wedbush
ZGNX Zogenix
$19.52 /

+0.33 (+1.72%)

02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
08/24/20 Raymond James
Zogenix initiated with a Market Perform at Raymond James
07/15/20 Stifel
Physician survey suggests Zogenix shares undervalued, says Stifel
AVDL Avadel Pharmaceuticals
$9.11 /

+0.28 (+3.17%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
QURE uniQure
$33.75 /

+0.53 (+1.60%)

03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
03/02/21 Chardan
uniQure price target raised to $100 from $85 at Chardan
12/22/20 Chardan
uniQure selloff on clinical hold brings good entry point, says Chardan
12/22/20 Jefferies
uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies
ZGNX Zogenix
$19.52 /

+0.33 (+1.72%)

XENE Xenon Pharmaceuticals
$17.94 /

+0.59 (+3.40%)

TSHA Taysha Gene Therapies
$20.21 /

-0.33 (-1.61%)

STOK Stoke Therapeutics
$38.92 /

+1.89 (+5.10%)

SAGE Sage Therapeutics
$74.85 /

+1.82 (+2.49%)

QURE uniQure
$33.75 /

+0.53 (+1.60%)

PRAX Praxis Precision Medicines
$32.86 /

+3.25 (+10.98%)

PASG Passage Bio
$17.55 /

+0.8 (+4.78%)

KRTX Karuna Therapeutics
$119.93 /

+2.66 (+2.27%)

CERE Cerevel Therapeutics
$13.73 /

+1.36 (+10.99%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

AVDL Avadel Pharmaceuticals
$9.11 /

+0.28 (+3.17%)

  • 10
    Mar
  • 02
    Mar
  • 22
    Jan
  • 20
    Nov
  • 16
    Oct
  • 24
    Sep
  • 29
    Apr
BIIB Biogen
$280.05 /

+4.17 (+1.51%)

ZGNX Zogenix
$19.52 /

+0.33 (+1.72%)

XENE Xenon Pharmaceuticals
$17.94 /

+0.59 (+3.40%)

STOK Stoke Therapeutics
$38.92 /

+1.89 (+5.10%)

SAGE Sage Therapeutics
$74.85 /

+1.82 (+2.49%)

QURE uniQure
$33.75 /

+0.53 (+1.60%)

PRAX Praxis Precision Medicines
$32.86 /

+3.25 (+10.98%)

PASG Passage Bio
$17.55 /

+0.8 (+4.78%)

KRTX Karuna Therapeutics
$119.93 /

+2.66 (+2.27%)

CERE Cerevel Therapeutics
$13.73 /

+1.36 (+10.99%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

AVDL Avadel Pharmaceuticals
$9.11 /

+0.28 (+3.17%)

ZGNX Zogenix
$19.52 /

+0.33 (+1.72%)

PRAX Praxis Precision Medicines
$32.86 /

+3.25 (+10.98%)

PASG Passage Bio
$17.55 /

+0.8 (+4.78%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

Conference/Events
Stifel to hold a virtual conference » 10:20
03/31/21
03/31
10:20
03/31/21
10:20
SAGE

Sage Therapeutics

$75.75 /

+2.72 (+3.72%)

, PRAX

Praxis Precision Medicines

$29.13 /

-0.48 (-1.62%)

, CERE

Cerevel Therapeutics

$13.49 /

+1.12 (+9.05%)

, KRTX

Karuna Therapeutics

$119.05 /

+1.78 (+1.52%)

, PASG

Passage Bio

$17.40 /

+0.65 (+3.88%)

, TSHA

Taysha Gene Therapies

$20.40 /

-0.14 (-0.68%)

, BIIB

Biogen

$276.92 /

+1.04 (+0.38%)

, XENE

Xenon Pharmaceuticals

$17.60 /

+0.25 (+1.44%)

, STOK

Stoke Therapeutics

$39.00 /

+1.97 (+5.32%)

, ZGNX

Zogenix

$19.38 /

+0.19 (+0.99%)

, AVDL

Avadel Pharmaceuticals

$9.00 /

+0.17 (+1.93%)

, QURE

uniQure

$34.10 /

+0.88 (+2.65%)

Stifel Virtual CNS Day…

Stifel Virtual CNS Day 2021 will be held on March 31-April 1.

ShowHide Related Items >><<
ZGNX Zogenix
$19.38 /

+0.19 (+0.99%)

XENE Xenon Pharmaceuticals
$17.60 /

+0.25 (+1.44%)

TSHA Taysha Gene Therapies
$20.40 /

-0.14 (-0.68%)

STOK Stoke Therapeutics
$39.00 /

+1.97 (+5.32%)

SAGE Sage Therapeutics
$75.75 /

+2.72 (+3.72%)

QURE uniQure
$34.10 /

+0.88 (+2.65%)

PRAX Praxis Precision Medicines
$29.13 /

-0.48 (-1.62%)

PASG Passage Bio
$17.40 /

+0.65 (+3.88%)

KRTX Karuna Therapeutics
$119.05 /

+1.78 (+1.52%)

CERE Cerevel Therapeutics
$13.49 /

+1.12 (+9.05%)

BIIB Biogen
$276.92 /

+1.04 (+0.38%)

AVDL Avadel Pharmaceuticals
$9.00 /

+0.17 (+1.93%)

SAGE Sage Therapeutics
$75.75 /

+2.72 (+3.72%)

02/26/21 Mizuho
Sage Therapeutics downgraded to Neutral from Buy at Mizuho
02/25/21 Oppenheimer
Sage Therapeutics price target raised to $102 from $90 at Oppenheimer
02/25/21 H.C. Wainwright
Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright
02/24/21 Stifel
Stifel cuts Sage target to $121, reiterates Buy after quarterly results
PRAX Praxis Precision Medicines
$29.13 /

-0.48 (-1.62%)

03/17/21 Piper Sandler
Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities
01/21/21 Wedbush
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush
11/17/20 Piper Sandler
Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
11/11/20
Fly Intel: Top five analyst initiations
CERE Cerevel Therapeutics
$13.49 /

+1.12 (+9.05%)

12/10/20 Goldman Sachs
Cerevel Therapeutics initiated with a Buy at Goldman Sachs
11/23/20 Jefferies
Cerevel Therapeutics initiated with a Buy at Jefferies
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Stifel
Cerevel Therapeutics initiated with a Buy at Stifel
KRTX Karuna Therapeutics
$119.05 /

+1.78 (+1.52%)

03/22/21 BofA
Karuna Therapeutics initiated with a Buy at BofA
03/01/21 Oppenheimer
Karuna Therapeutics price target raised to $148 from $135 at Oppenheimer
02/26/21 Mizuho
Karuna Therapeutics price target raised to $150 from $116 at Mizuho
02/26/21 JMP Securities
Karuna Therapeutics price target raised to $167 from $122 at JMP Securities
PASG Passage Bio
$17.40 /

+0.65 (+3.88%)

03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
02/04/21
Fly Intel: Top five analyst initiations
TSHA Taysha Gene Therapies
$20.40 /

-0.14 (-0.68%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
BIIB Biogen
$276.92 /

+1.04 (+0.38%)

03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/25/21 Mizuho
Two 'low probability' Biogen events could drive upside, says Mizuho
03/23/21 Piper Sandler
Neurologist survey shows erosion for Biogen franchises, says Piper Sandler
02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
XENE Xenon Pharmaceuticals
$17.60 /

+0.25 (+1.44%)

10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
STOK Stoke Therapeutics
$39.00 /

+1.97 (+5.32%)

03/29/21 Canaccord
Stoke Therapeutics weakness a buying opportunity, says Canaccord
03/11/21 Canaccord
Stoke Therapeutics price target raised to $76 from $72 at Canaccord
03/10/21 Credit Suisse
Stoke Therapeutics price target raised to $58 from $49 at Credit Suisse
02/10/21 Wedbush
Stoke Therapeutics downgraded to Neutral at Wedbush
ZGNX Zogenix
$19.38 /

+0.19 (+0.99%)

02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
08/24/20 Raymond James
Zogenix initiated with a Market Perform at Raymond James
07/15/20 Stifel
Physician survey suggests Zogenix shares undervalued, says Stifel
AVDL Avadel Pharmaceuticals
$9.00 /

+0.17 (+1.93%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
QURE uniQure
$34.10 /

+0.88 (+2.65%)

03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
03/02/21 Chardan
uniQure price target raised to $100 from $85 at Chardan
12/22/20 Chardan
uniQure selloff on clinical hold brings good entry point, says Chardan
12/22/20 Jefferies
uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies
ZGNX Zogenix
$19.38 /

+0.19 (+0.99%)

XENE Xenon Pharmaceuticals
$17.60 /

+0.25 (+1.44%)

TSHA Taysha Gene Therapies
$20.40 /

-0.14 (-0.68%)

STOK Stoke Therapeutics
$39.00 /

+1.97 (+5.32%)

SAGE Sage Therapeutics
$75.75 /

+2.72 (+3.72%)

QURE uniQure
$34.10 /

+0.88 (+2.65%)

PRAX Praxis Precision Medicines
$29.13 /

-0.48 (-1.62%)

PASG Passage Bio
$17.40 /

+0.65 (+3.88%)

KRTX Karuna Therapeutics
$119.05 /

+1.78 (+1.52%)

CERE Cerevel Therapeutics
$13.49 /

+1.12 (+9.05%)

BIIB Biogen
$276.92 /

+1.04 (+0.38%)

AVDL Avadel Pharmaceuticals
$9.00 /

+0.17 (+1.93%)

  • 10
    Mar
  • 02
    Mar
  • 22
    Jan
  • 20
    Nov
  • 16
    Oct
  • 24
    Sep
  • 29
    Apr
BIIB Biogen
$276.92 /

+1.04 (+0.38%)

ZGNX Zogenix
$19.38 /

+0.19 (+0.99%)

XENE Xenon Pharmaceuticals
$17.60 /

+0.25 (+1.44%)

STOK Stoke Therapeutics
$39.00 /

+1.97 (+5.32%)

SAGE Sage Therapeutics
$75.75 /

+2.72 (+3.72%)

QURE uniQure
$34.10 /

+0.88 (+2.65%)

PRAX Praxis Precision Medicines
$29.13 /

-0.48 (-1.62%)

PASG Passage Bio
$17.40 /

+0.65 (+3.88%)

KRTX Karuna Therapeutics
$119.05 /

+1.78 (+1.52%)

CERE Cerevel Therapeutics
$13.49 /

+1.12 (+9.05%)

BIIB Biogen
$276.92 /

+1.04 (+0.38%)

AVDL Avadel Pharmaceuticals
$9.00 /

+0.17 (+1.93%)

ZGNX Zogenix
$19.38 /

+0.19 (+0.99%)

PRAX Praxis Precision Medicines
$29.13 /

-0.48 (-1.62%)

PASG Passage Bio
$17.40 /

+0.65 (+3.88%)

BIIB Biogen
$276.92 /

+1.04 (+0.38%)

Conference/Events
Hanson Wade to hold a virtual conference » 10:34
03/24/21
03/24
10:34
03/24/21
10:34
BLUE

Bluebird Bio

$29.07 /

-0.21 (-0.72%)

, AGTC

Applied Genetic

$5.30 /

-0.185 (-3.37%)

, PFE

Pfizer

$35.69 /

+0.33 (+0.93%)

, RARE

Ultragenyx

$114.32 /

-2.76 (-2.36%)

, TSHA

Taysha Gene Therapies

$22.65 /

+0.22 (+0.98%)

Gene Therapy Patient…

Gene Therapy Patient Engagement Virtual Conference will be held on March 23-25.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$22.65 /

+0.22 (+0.98%)

RARE Ultragenyx
$114.32 /

-2.76 (-2.36%)

PFE Pfizer
$35.69 /

+0.33 (+0.93%)

BLUE Bluebird Bio
$29.07 /

-0.21 (-0.72%)

AGTC Applied Genetic
$5.30 /

-0.185 (-3.37%)

BLUE Bluebird Bio
$29.07 /

-0.21 (-0.72%)

03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
03/10/21 Stifel
Bluebird Bio price target raised to $31 from $26 at Stifel
03/10/21 Oppenheimer
Oppenheimer says Bluebird 'reputational damage likely to persist' after AML case
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
AGTC Applied Genetic
$5.30 /

-0.185 (-3.37%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
PFE Pfizer
$35.69 /

+0.33 (+0.93%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
RARE Ultragenyx
$114.32 /

-2.76 (-2.36%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
TSHA Taysha Gene Therapies
$22.65 /

+0.22 (+0.98%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
TSHA Taysha Gene Therapies
$22.65 /

+0.22 (+0.98%)

RARE Ultragenyx
$114.32 /

-2.76 (-2.36%)

PFE Pfizer
$35.69 /

+0.33 (+0.93%)

BLUE Bluebird Bio
$29.07 /

-0.21 (-0.72%)

AGTC Applied Genetic
$5.30 /

-0.185 (-3.37%)

  • 28
    Jan
  • 29
    Oct
  • 24
    Sep
  • 19
    May
PFE Pfizer
$35.69 /

+0.33 (+0.93%)

BLUE Bluebird Bio
$29.07 /

-0.21 (-0.72%)

TSHA Taysha Gene Therapies
$22.65 /

+0.22 (+0.98%)

PFE Pfizer
$35.69 /

+0.33 (+0.93%)

BLUE Bluebird Bio
$29.07 /

-0.21 (-0.72%)

AGTC Applied Genetic
$5.30 /

-0.185 (-3.37%)

PFE Pfizer
$35.69 /

+0.33 (+0.93%)

BLUE Bluebird Bio
$29.07 /

-0.21 (-0.72%)

Over a month ago
Hot Stocks
Taysha Gene Therapies announces collaboration to advance AAV gene therapies » 07:17
03/09/21
03/09
07:17
03/09/21
07:17
TSHA

Taysha Gene Therapies

$24.97 /

-3.765 (-13.10%)

Taysha Gene Therapies…

Taysha Gene Therapies announced a multi-year collaboration to advance next-generation mini-gene payloads for AAV gene therapies for the treatment of neurodevelopmental disorders. Taysha will have an exclusive option on new payloads, constructs, and intellectual property associated with, and arising from, the research conducted under this agreement. The collaboration with Yong-Hui Jiang, professor and chief of medical genetics at Yale University, follows the previously announced collaborations with Cleveland Clinic and UT Southwestern Gene Therapy Program to support the creation of a novel next-generation mini-gene platform designed to overcome key challenges in gene therapy. Under the terms of this most recent agreement, a team of researchers from Yale University will create mini-gene payloads designed to treat neurodevelopmental disorders including intellectual disability. UTSW will produce viral vector constructs that incorporate the mini-gene payloads and evaluate the constructs in in vivo and in vitro efficacy models.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$24.97 /

-3.765 (-13.10%)

TSHA Taysha Gene Therapies
$24.97 /

-3.765 (-13.10%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
TSHA Taysha Gene Therapies
$24.97 /

-3.765 (-13.10%)

  • 24
    Sep
TSHA Taysha Gene Therapies
$24.97 /

-3.765 (-13.10%)

Recommendations
Taysha Gene Therapies price target raised to $60 from $45 at Chardan » 08:37
03/04/21
03/04
08:37
03/04/21
08:37
TSHA

Taysha Gene Therapies

$24.89 /

-0.89 (-3.45%)

Chardan analyst Gbola…

Chardan analyst Gbola Amusa raised the firm's price target on Taysha Gene Therapies to $60 from $45 and keeps a Buy rating on the shares after the company reported FY20 results and updated on its progress towards its ultimate goal of launching a gene therapy program every two years. Amusa has increased conviction as Taysha "continues towards a catalyst-rich" 2021 and 2022, the analyst tells investors.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$24.89 /

-0.89 (-3.45%)

TSHA Taysha Gene Therapies
$24.89 /

-0.89 (-3.45%)

02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
01/04/21 Oppenheimer
Taysha Gene Therapies initiated with an Outperform at Oppenheimer
TSHA Taysha Gene Therapies
$24.89 /

-0.89 (-3.45%)

  • 24
    Sep
TSHA Taysha Gene Therapies
$24.89 /

-0.89 (-3.45%)

Earnings
Taysha Gene Therapies reports Q4 EPS (12c), consensus (37c) » 07:10
03/03/21
03/03
07:10
03/03/21
07:10
TSHA

Taysha Gene Therapies

$25.78 /

-0.99 (-3.70%)

Cash and cash…

Cash and cash equivalents: As of December 31, 2020, Taysha had $251.3 million in cash and cash equivalents, which included $165.9 million in net proceeds from the company's IPO completed in September 2020. .In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy," said RA Session II, President, Founder and CEO of Taysha. "We expect 2021 to be a transformational year for Taysha, as we anticipate reporting first-in-human clinical data for TSHA-101 in GM2 gangliosidosis and initiating Phase 1/2 trials in CLN1 disease, Rett syndrome and SURF1-associated Leigh syndrome. We will be submitting multiple IND/CTAs across three CNS franchises, and advancing four gene therapies into IND-/CTA-enabling studies and initiating work on additional targets. We continue to enhance our platform of next-generation technologies to optimize key components of our approach with AAV-based gene therapies. With recent additions to our team and Board of Directors and the formation of our Scientific Advisory Board, we believe we have the resources needed to achieve our corporate initiatives this year. Lastly, we will continue to evaluate other opportunities to maximize the value of our pipeline and technology platforms. We look forward to providing updates on our progress throughout the year and at an R&D day later this year."

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$25.78 /

-0.99 (-3.70%)

TSHA Taysha Gene Therapies
$25.78 /

-0.99 (-3.70%)

02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
01/04/21 Oppenheimer
Taysha Gene Therapies initiated with an Outperform at Oppenheimer
  • 24
    Sep
TSHA Taysha Gene Therapies
$25.78 /

-0.99 (-3.70%)

Initiation
William Blair starts Taysha with Outperform, $46 fair-value estimate » 17:22
02/23/21
02/23
17:22
02/23/21
17:22
TSHA

Taysha Gene Therapies

$26.98 /

-2.12 (-7.29%)

William Blair analyst…

William Blair analyst Raju Prasad initiated coverage of Taysha Gene Therapies with an Outperform rating and $46 fair-value estimate. Taysha is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic central nervous system disorders, Prasad tells investors in a research note. The company is advancing a portfolio of 19 gene therapy product candidates, the analyst adds. He sees TSHA-102 in Rett syndrome as the largest market opportunity, with estimated revenue of $2.4B in 2031. Prasad also sees the recent FDA draft guidance on neurodegenerative diseases as a "positive tailwind" for Taysha.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$26.98 /

-2.12 (-7.29%)

TSHA Taysha Gene Therapies
$26.98 /

-2.12 (-7.29%)

02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
01/04/21 Oppenheimer
Taysha Gene Therapies initiated with an Outperform at Oppenheimer
10/19/20 Chardan
Taysha Gene Therapies initiated with a Buy at Chardan
  • 24
    Sep
TSHA Taysha Gene Therapies
$26.98 /

-2.12 (-7.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.